ArticleTherapeutic advances in gastroenterology2025
OLGA and OLGIM staging systems on the risk assessment of gastric cancer: a systematic review and meta‑analysis of prospective cohorts.
Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Updating the Prevalence ofJournal of clinical medicine · 2026Article
- Prevalence and Progression of Subtypes of Gastric Premalignant Lesions: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Review
- From screening to surveillance: integrated prevention ofThe Lancet regional health. Western Pacific · 2026Review
- Management of Gastric Precancerous Lesions and Early Cancer: Practice-Oriented Answers to Clinical Questions.Cancers · 2026Review
- Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system.Histopathology · 2026Review
- A novel risk stratification strategy for precision prevention of gastric cancer based on clinicopathological features and IGFBP7.Scientific reports · 2026Article
- Early Detection of Gastric Cancer: Linking Epidemiology, Pathophysiology, and Innovations in Digestive Endoscopy.Diseases (Basel, Switzerland) · 2026Review
- Gastric intestinal metaplasia: Management and surveillance strategies.World journal of gastrointestinal pathophysiology · 2026Review
- Impact of incisura biopsy on the surveillance of precursor lesions and gastric cancer risk assessment.Gastroenterology report · 2026Article
- Autoimmune gastritis: a comprehensive review of pathophysiology, risk stratification, and management.Frontiers in immunology · 2026Review
- Mucin phenotype-based deep learning framework for intestinal metaplasia-carcinogenesis progression prediction.NPJ precision oncology · 2025Article
- Texture and Color Enhancement Imaging-Assisted Endocytoscopy Improves Characterization of Gastric Precancerous Conditions: A Set of Interesting Comparative Images.Diagnostics (Basel, Switzerland) · 2025Article
- Comment on: OLGA and OLGIM staging systems on the risk assessment of gastric cancer: a systematic review and meta-analysis of prospective cohorts.Therapeutic advances in gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) are established classification systems used to evaluate atrophic gastritis and intestinal metaplasia, respectively. Objectives: We evaluated the association of OLGA and OLGIM scores and the risk of gastric cancer (GC) in only prospective cohort studies. Design: Systematic review and meta-analysis. Data sources and methods: We systematically searched four databases for prospective cohorts that evaluated the use of OLGA and OLGIM staging systems in predicting the risk of GC. We primarily compared OLGA/OLGIM III-IV versus OLGA/OLGIM 0-II categories and GC events. Pooled risk ratios (RR) and absolute risk differences with their 95% confidence intervals (CIs) were calculated. Results: Eight studies were included ( Conclusion: Higher stages in OLGA and OLGIM systems are associated with a significantly increased risk of developing HGD and GC, validating these scoring systems for the assessment of GC risk and the design of endoscopic surveillance programs. Trial PROSPERO registration: CRD42024565771.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.